Private company

Deciphera Pharmaceuticals, Inc.

We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.4 From its latest annual report

Last updated Oct 19, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersWaltham, United States2
  • Incorporated inDE3
  • Business address200 Smith Street, Waltham, Ma 024513
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI529900QR4WAPYY0CBF252
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 64978322

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, we design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through our patient-inspired approach, we seek to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, our switch-control tyrosine kinase inhibitor, was discovered using our proprietary drug discovery platform and designed for the treatment of GIST. QINLOCK is approved in Australia, Canada, China, the European Union (EU), Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, the U.K., and the U.S. for t…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-129.1%Operating margin5
-119.3%Net margin6
21.9%Revenue growth, 20235
-55.5%Return on equity5
-$147.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue1¢$3.7M
  • Research and development62¢$234.1M
  • Selling, general and admin36¢$136.5M
  • Income tax0¢$431.0K

Out of $163.4M in revenue.56 The company lost money this year.

Financial statements

Revenue789105$163.4M in 2023
0$50.0M$100.0M$150.0M$200.0M2017: $0$020172018: $0$020182019: $25.0M$25.0M20192020: $42.1M$42.1M2020+68%2021: $96.1M$96.1M2021+128%2022: $134.0M$134.0M2022+39%2023: $163.4M$163.4M2023+22%
Operating income1189105-$211.0M in 2023+314% since 2017
-$400.0M-$300.0M-$200.0M-$100.0M02017: -$50.9M-$50.9M20172018: -$104.1M-$104.1M2018+104%2019: -$200.7M-$200.7M2019+93%2020: -$271.2M-$271.2M2020+35%2021: -$300.1M-$300.1M2021+11%2022: -$182.7M-$182.7M2022−39%2023: -$211.0M-$211.0M2023+15%
Net income11891056-$194.9M in 2023+288% since 2017
-$300.0M-$200.0M-$100.0M02017: -$50.3M-$50.3M20172018: -$99.9M-$99.9M2018+99%2019: -$192.3M-$192.3M2019+93%2020: -$266.5M-$266.5M2020+39%2021: -$300.0M-$300.0M2021+13%2022: -$178.9M-$178.9M2022−40%2023: -$194.9M-$194.9M2023+9%
Fiscal year2017201820192020202120222023
Revenue$07$08$25.0M9$42.1M10$96.1M5$134.0M5$163.4M5
Cost of revenue$08$09$225.0K10$2.9M5$8.8M5$3.7M5
Research and development$39.5M11$82.9M8$157.6M9$199.0M10$257.0M5$187.8M5$234.1M5
Selling, general and admin$21.2M8$68.1M9$114.1M10$136.3M5$120.2M5$136.5M5
Operating expenses$396.2M5$316.8M5$374.3M5
Operating income-$50.9M11-$104.1M8-$200.7M9-$271.2M10-$300.1M5-$182.7M5-$211.0M5
Interest$95.0K11$84.0K8$67.0K9$09$09
Income before tax-$300.0M5-$178.2M5-$194.5M5
Income tax$014$08$09$010$05$722.0K5$431.0K5
Net income-$50.3M11-$99.9M8-$192.3M9-$266.5M10-$300.0M5-$178.9M5-$194.9M6
Earnings per share-$4.7810-$5.165-$2.375-$2.295
Earnings per share (diluted)-$4.7810-$5.165-$2.375-$2.295
Shares (weighted, basic)58.1M shares575.5M shares585.1M shares5
Shares (weighted, diluted)58.1M shares575.5M shares585.1M shares5

Compare Deciphera Pharmaceuticals, Inc. with another company

Leadership

Who has led Deciphera Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Douglas Taylor2019
  2. Steven L. Hoerter2019–2024

President

  1. Michael Douglas Taylor2019
  2. Steven L. Hoerter2019–2024

Chief financial officer

  1. Thomas Patrick Kelly2017–2024
20202025
Board members and other officers (18)

Former names

  • Deciphera Pharmaceuticals, LLCSep 29, 2015 to Aug 15, 20173

Timeline

  1. Mar 20, 2019New chief executive Steven L. Hoerter becomes CEO16
  2. Feb 1, 2019New chief executive Michael Douglas Taylor becomes CEO15

Filings

246 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 29 major events, 118 insider forms, 27 large holders, 61 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Jun 21, 202415-12G EDGAR
  3. Jun 13, 2024EFFECT EDGAR
  4. Jun 11, 2024S-8 POS EDGAR
  5. Jun 11, 2024S-8 POS EDGAR
  6. Jun 11, 2024S-8 POS EDGAR
  7. Jun 11, 2024S-8 POS EDGAR
  8. Jun 11, 2024S-8 POS EDGAR
  9. Jun 11, 2024S-8 POS EDGAR
  10. Jun 11, 2024S-8 POS EDGAR
  11. Jun 11, 2024S-8 POS EDGAR
  12. Jun 11, 2024POS AM EDGAR
  13. Jun 11, 2024POSASR EDGAR
  14. Jun 11, 20248-K EDGAR
  15. Jun 11, 2024SC 14D9/A EDGAR
  16. Jun 11, 2024SC TO-T/A EDGAR
  17. Jun 11, 20244 EDGAR
  18. Jun 11, 20244 EDGAR
  19. Jun 11, 20244 EDGAR
  20. Jun 11, 20244 EDGAR

The 246 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

53 open-market trades by officers, directors and large owners since October 2021: 4 buys and 49 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 16, 2024Kelly Thomas PatrickChief Financial OfficerSale3,010$15.62$47.0KForm 4
Feb 16, 2024Martin Daniel C.Chief Commercial OfficerSale2,267$15.62$35.4KForm 4
Feb 16, 2024Sherman Matthew LEVP & Chief Medical OfficerSale2,615$15.62$40.8KForm 4
Feb 16, 2024Pitman JamaSVP, Chief Development OfficerSale2,267$15.62$35.4KForm 4
Jan 16, 2024Sherman Matthew LEVP & Chief Medical OfficerSale2,435$14.47$35.2KForm 4
Jan 16, 2024Pitman JamaSVP, Chief Development OfficerSale1,624$14.47$23.5KForm 4
Jan 16, 2024Kelly Thomas PatrickChief Financial OfficerSale2,435$14.47$35.2KForm 4
Jan 16, 2024Martin Daniel C.Chief Commercial OfficerSale1,624$14.47$23.5KForm 4
Dec 13, 2023Hoerter Steven L.President and CEOSale30,664$15.37$471.3KForm 4
Dec 13, 2023Pitman JamaSVP, Chief Development OfficerSale1,662$15.37$25.5KForm 4
Dec 13, 2023Kelly Thomas PatrickChief Financial OfficerSale2,792$15.37$42.9KForm 4
Dec 13, 2023Martin Daniel C.Chief Commercial OfficerSale1,727$15.37$26.5KForm 4
Dec 13, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,792$15.37$42.9KForm 4
Nov 30, 2023Martin Daniel C.Chief Commercial OfficerSale17,801$12.57$223.8KForm 4
Oct 30, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,360$12.02$28.4KForm 4
Oct 30, 2023Pitman JamaSVP, Chief Development OfficerSale1,407$12.02$16.9KForm 4
Oct 30, 2023Martin Daniel C.Chief Commercial OfficerSale1,407$12.02$16.9KForm 4
Oct 30, 2023Kelly Thomas PatrickChief Financial OfficerSale2,316$12.02$27.8KForm 4
Oct 30, 2023Hoerter Steven L.President and CEOSale21,573$12.02$259.3KForm 4
Oct 2, 2023Sherman Matthew LEVP & Chief Medical OfficerSale2,942$12.68$37.3KForm 4

All 53 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43